Key Takeaways NVCR wins Japan National Health Insurance reimbursement for Optune Lua in NSCLC patients.Coverage in Japan could expand patient access and drive adoption of Novocure's TTFields therapy platform.NVCR's Optune Lua uses alternating electric fields to disrupt cancer cell division in NSCLC.Novocure (NVCR) recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua through the country’s National Health Insurance program.In Japan, Optune Lua is ind ...

Core Insights - NovoCure Limited achieved record net revenue of $655 million in 2025, driven by substantial active patient growth in international markets like France and Japan [4] - The company transitioned to a multi-indication platform following FDA approval of Optune Pax for locally advanced pancreatic cancer in a record 180-day review cycle [4] - Projected 2026 revenue is estimated to be between $675 million and $705 million, assuming low to mid-single-digit growth in the core glioblastoma (GBM) business and an additional $15 million to $25 million from new indications [4] Financial Performance - The gross margin decreased to 75% for 2025, attributed to lower prior-period collections and increased costs from HIV rates and tariffs [5] - The company is targeting a range of negative $20 million to breakeven for adjusted EBITDA in full-year 2026 through diligent expense management [4] Strategic Initiatives - The leadership team was restructured to combine scientific and clinical organizations under a dual Chief Innovation and Medical Officer role to accelerate R&D-to-clinical cycles [4] - Planned international expansion includes product launches in Japan, Spain, Czechia, and British Columbia to diversify the global revenue base [4] - Marketing spend for Optune Lua in the U.S. and Germany was rightsized due to slower-than-projected adoption in the non-small cell lung cancer market [4] Clinical Development - Anticipated clinical catalysts include Phase II PANOVA-4 top-line data in March and Phase III TRIDENT data in the second quarter of 2026 [4] - Enrollment for the Phase III KEYNOTE D58 trial in newly diagnosed GBM is expected to be completed by the end of 2026 [4] Operational Challenges - Addressed a temporary Medicare billing administrative issue, securing retroactive reinstatement to ensure no negative impact on revenue recognition [4] - Acknowledged a 1-2 year lag in routine commercial insurance coverage for new indications, requiring initial reliance on appeals and NCCN guideline inclusion [4]

Core Insights - NovoCure's glioblastoma (GBM) business remains a core focus, with active patient growth in major markets, particularly outside the U.S. [1] - The company reported record net revenue of $655 million for 2025, an 8% increase from 2024, and anticipates continued momentum into 2026 [4][11] - Management expects 2026 to be a "catalyst-rich" year with multiple regulatory and clinical milestones, including the FDA approval of Optune Pax for locally advanced pancreatic cancer [3][5] Financial Performance - Fourth-quarter net revenue was $174 million, contributing to the full-year net revenue of $655 million, both reflecting an 8% year-over-year growth [11] - Gross margin for 2025 was 75%, down from 77% in 2024, attributed to lower prior-period collections and higher costs [14] - The company reported a net loss of $136 million for the year, with an adjusted EBITDA of negative $34 million [16] Market Opportunities and Product Launches - NovoCure is preparing to launch Optune Pax in the U.S. and Japan, with an estimated total addressable market of about 15,000 patients annually for locally advanced pancreatic cancer [9][6] - The company expects modest contributions from new GBM markets and $15 million to $25 million in net revenue from non-GBM products in 2026 [17] - Optune Lua generated $10.4 million in revenue for the full year, with $5.8 million from non-small cell lung cancer patients [12] Strategic Changes and Leadership - CEO Frank Leonard highlighted 2025 as the company's most successful year, with plans to evolve into a "multi-indication platform company" [2] - Following the resignation of the Chief Medical Officer, the company combined its scientific and clinical organizations to enhance R&D execution [2] - The company is leveraging its existing sales force for the Optune Pax launch without adding incremental sales headcount [8]

Financial Data and Key Metrics Changes - The company generated a record $655 million in net revenues for 2025, representing an 8% increase from 2024 [5][17] - Fourth quarter net revenue was $174 million, also reflecting an 8% year-over-year growth [17] - Adjusted EBITDA was negative $34 million for the full year, with a guidance of -$20 million to break even for 2026 [21][23] Business Line Data and Key Metrics Changes - Optune Lua revenue for the full year was $10.4 million, including $5.8 million from non-small cell lung cancer patients [17] - The company expects contributions from new indications, including Optune Lua and Optune Pax, to be in the range of $15 million to $25 million for 2026 [19][29] Market Data and Key Metrics Changes - Active patient growth in major markets included 10% in Germany, 19% in France, and 29% in Japan, while the U.S. saw a 4% growth [11] - The company anticipates modest contributions from new market launches in Spain, Czechia, and British Columbia [12] Company Strategy and Development Direction - The company aims to drive profitability and has set a goal to reach adjusted EBITDA breakeven in 2026 [23][56] - The recent approval of Optune Pax for locally advanced pancreatic cancer is expected to significantly contribute to long-term growth [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of Optune products and the importance of establishing coverage policies with payers [49] - The company is focused on maintaining momentum and achieving regulatory, clinical, and commercial milestones in 2026 [7][55] Other Important Information - The company resolved a Medicare billing issue with CMS, ensuring no negative impact on revenue recognition [18] - Dr. Nicolas Leupin resigned as Chief Medical Officer, and Dr. Uri Weinberg will assume the role, combining scientific and clinical organizations to enhance R&D execution [9] Q&A Session Summary Question: Why is the company providing guidance now? - Management indicated that setting clear expectations for growth is essential as the company matures in the public market [27][28] Question: What are the assumptions behind the revenue guidance? - The guidance includes growth from established GBM markets, new markets, and contributions from new indications [29][30] Question: How will Optune Pax be prescribed based on the approved label? - The company plans to target a highly motivated patient population with limited treatment options, emphasizing the unique value proposition of Optune Pax [39] Question: How much sales force is allocated for Optune Pax? - The existing sales team trained for Optune Lua will lead the Optune Pax launch without adding new headcount [44]

Financial Data and Key Metrics Changes - The company generated a record $655 million in net revenues for 2025, an 8% increase from 2024 [5][17] - Fourth quarter net revenue was $174 million, also reflecting an 8% year-over-year growth [17] - Gross margin for Q4 was 76% and 75% for the full year, down from 79% and 77% in 2024, primarily due to decreased prior period collections in the US and increased costs [19] - The net loss for Q4 was $24 million, with a loss per share of $0.22, and a full-year net loss of $136 million, or $1.22 per share [21] Business Line Data and Key Metrics Changes - Optune Lua revenue for the full year was $10.4 million, including $5.8 million from non-small cell lung cancer patients [17] - The company recognized $3.5 million from Optune Lua claims in Q4, including $2.4 million from non-small cell lung cancer [17] - Research and development costs increased by 19% in Q4 to $61 million, driven by costs related to phase 3 trials [20] Market Data and Key Metrics Changes - Active patient growth in major markets included 10% in Germany, 19% in France, and 29% in Japan, while the US saw a 4% growth [11] - The company expects growth rates to stabilize in the low to mid-single digits as markets mature [11] Company Strategy and Development Direction - The company aims to drive profitable growth and achieve adjusted EBITDA breakeven in 2026 [22] - New product launches are planned for Optune Gio in Spain, Czechia, and British Columbia, and Optune Lua in Japan [8][12] - The approval of Optune Pax for locally advanced pancreatic cancer is expected to significantly contribute to long-term growth [6][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming regulatory, clinical, and commercial milestones for 2026, including the approval of Optune Pax and anticipated data readouts from ongoing trials [6][54] - The company is focused on establishing coverage policies for new indications and believes that the market opportunity for pancreatic cancer is significant [39][49] Other Important Information - The Chief Medical Officer resigned, and the company combined its scientific and clinical organizations to enhance R&D execution [9] - The company resolved a Medicare billing issue with CMS, ensuring no negative impact on revenue recognition [18] Q&A Session Summary Question: Guidance for 2026 - Management indicated that providing guidance now reflects a commitment to returning to steady growth and achieving adjusted EBITDA breakeven [26][27] Question: Optune Gio Revenue Growth - Management clarified that the guidance for low to mid-single digit growth is not a signal of market moderation but reflects the potential for increased patient prescriptions [34] Question: Optune Pax Prescription Strategy - Management emphasized the importance of targeting a highly motivated patient population for Optune Pax and leveraging existing sales teams for the launch [39][44] Question: Sales Force Allocation for Optune Pax - The existing sales team trained for Optune Lua will lead the Optune Pax launch without adding new headcount [44] Question: Revenue Contributions from Optune Pax - Management noted that revenue from Optune Pax will initially lag as coverage policies are established, with expectations for routine coverage taking 1-2 years [49][50]

forward -looking statements In addition to historical facts or statements of current condition, this presentation may contain forward - looking statements. Fo rward - looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific pro gress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, man ufa cturing developmen ...

Core Viewpoint - Novocure (NVCR) has received FDA approval for its portable therapeutic device, Optune Pax, for treating adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, ahead of the expected timeline of Q2 2026 [1][2] Company Developments - The FDA approval is based on the successful phase III study, PANOVA-3, which showed that Optune Pax combined with gem/nab-pac significantly improved overall survival compared to gem/nab-pac alone [2][9] - Novocure has other commercialized therapies using Tumor Treating Fields (TTFields), including Optune Gio for glioblastoma multiforme and Optune Lua for metastatic non-small cell lung cancer [3] - The company is also developing therapies for treating metastatic pancreatic cancer and newly diagnosed glioblastoma multiforme [3] Clinical Data - The PANOVA-3 study demonstrated a median overall survival (mOS) of 16.2 months for patients treated with Optune Pax and gem/nab-pac, compared to 14.2 months for those receiving gem/nab-pac alone [8][10] - The one-year survival rate was 68.1% for the Optune Pax group versus 60.2% for the gem/nab-pac group [10] - Additionally, the median time to pain progression improved to 15.2 months with Optune Pax compared to 9.1 months for gem/nab-pac alone [10] Market Potential - The pancreatic cancer market is projected to grow from $3.01 billion to $9.57 billion between 2025 and 2034, at a CAGR of 13.7%, driven by increasing cases and advancements in treatment options [12] - The approval of Optune Pax is expected to enhance Novocure's market prospects, given the limited treatment options currently available for pancreatic cancer [12] Financial Performance - Novocure reported preliminary net revenues of $174.4 million for Q4 and full-year 2025, reflecting an 8% year-over-year increase, with total revenues for the year reaching $655 million [13]

Core Viewpoint - A newly approved non-invasive treatment for locally advanced pancreatic cancer, utilizing a wearable device to continuously deliver electric fields that disrupt tumor cell division, has gained attention. This treatment, approved by the FDA for use in the U.S., is not yet available in China but offers insights for domestic professionals [2]. Group 1: Treatment Mechanism - The Optune Pax system employs Tumor Treating Fields (TTFields) technology, delivering low-intensity alternating electric fields to the tumor area via electrode arrays attached to the skin [3]. - The core mechanism of action is that the electric field affects rapidly dividing cancer cells while having a limited impact on normal cells, which divide more slowly [4][5]. Group 2: Device Characteristics - Optune Pax is a lightweight and portable system, allowing patients to receive treatment while maintaining daily activities [6]. - The device applies physical forces to charged cellular structures, disrupting spindle formation during mitosis, blocking chromosome separation, and leading to cancer cell death [7]. Group 3: Clinical Trial Results - The approval of Optune Pax is based on the pivotal Phase III clinical trial PANOVA-3, which demonstrated a significant improvement in overall survival [9]. - In the intention-to-treat population, the median overall survival was 18.3 months for the treatment group compared to 15.1 months for the control group, indicating a clinically meaningful improvement [10]. - The one-year survival rate was 68.1% for the treatment group versus 60.2% for the control group [11]. - Patients experienced delayed progression of pain and improved quality of life indicators, with the treatment showing good overall tolerability [12]. Group 4: Challenges and Future Considerations - Despite positive clinical trial results, real-world application faces challenges, including balancing efficacy and treatment burden, which will directly impact its adoption [17]. - Key observations for future development include the need for real-world data to validate the long-term value of TTFields in pancreatic cancer treatment [18]. - The treatment landscape for pancreatic cancer has seen little innovation over decades, making this development noteworthy [19].

Summary of Novocure's Presentation at Jefferies 2025 Global Healthcare Conference Company Overview - **Company**: Novocure - **Focus**: Development and commercialization of Tumor Treating Fields (TTFields), an innovative cancer therapy utilizing electric fields to disrupt cancer cell division and induce immunogenic cell death [3][4] Core Insights and Mechanism of Action - **Mechanism**: TTFields selectively target cancer cells by exploiting their electrical properties, allowing for a multifaceted approach to treatment [3][4] - **Combination Therapy**: TTFields can be combined with other systemic therapies without additive toxicity, enhancing treatment efficacy [4] Product Delivery and Revenue Model - **Device Description**: TTFields are delivered via a medical device consisting of an electric field generator and transducer arrays, which can be used at home [5][6] - **Revenue Model**: The company operates on a recurring revenue model by charging a monthly fee for the therapy device [6] Market Presence and Growth - **Established Market**: Novocure has a strong foundation in glioblastoma (GBM) with an annual run rate exceeding $600 million, recognized as the standard of care in multiple countries [9][10] - **Geographical Expansion**: The company has expanded its market presence to Germany, Japan, France, and Spain, with plans for further growth in major markets [7][10] Upcoming Product Launches - **New Indications**: Novocure plans to launch TTFields for non-small cell lung cancer (NSCLC), locally advanced pancreatic cancer, and brain metastases, aiming for four products on the market by the end of 2026 [8][14][27] - **Clinical Data**: Positive clinical data supports the efficacy of TTFields in various cancers, showing significant survival benefits [11][12][13] Financial Investments and R&D - **R&D Investment**: Over the past five years, Novocure has invested $1 billion in research and development to advance its TTFields platform [10] - **Future Catalysts**: The company anticipates a catalyst-rich year ahead with multiple data readouts and product launches expected in 2026 [19][27] Challenges and Strategic Focus - **Market Competition**: The launch of TTFields in the NSCLC market has faced challenges due to competition with established drug therapies [15][18] - **Reimbursement Strategy**: Novocure is navigating the reimbursement landscape, with expectations of a year for commercial payers and two years for Medicare coverage [31][32] Conclusion - **Vision**: Novocure aims to transform cancer treatment by providing innovative therapies that extend survival and improve quality of life for patients with aggressive cancers [28][30] - **Commitment**: The company is dedicated to advancing its pipeline and enhancing treatment options for patients, leveraging its unique technology and clinical data [28][34]

Financial Data and Key Metrics Changes - The company reported net revenues of $167 million for Q3 2025, an increase of 8% year-over-year, primarily driven by a 5% growth in active GBM patients [31][32] - Gross margin for the quarter was 73%, reflecting a reduction due to the global rollout of HFE arrays and increased tariffs [31][32] - The net loss for the quarter was $37 million, with a loss per share of $0.33, while adjusted EBITDA was negative $3 million, ahead of internal plans [33][34] Business Line Data and Key Metrics Changes - The GBM business saw a patient count increase to 4,277, with growth contributions from France (27%), Japan (8%), and Germany (7%) [6][31] - Non-small cell lung cancer (NSCLC) launch was behind expectations, ending Q3 with only 100 patients on therapy, 94 in the U.S. and 6 in Germany [8][31] Market Data and Key Metrics Changes - The company received a positive national coverage decision from the Spanish Ministry of Health, expecting Spain to deliver annual net revenue approximately half that of France at maturity [6] - The U.S. active patient count for GBM remained flat compared to Q3 2024, indicating a need for improved patient outreach [7] Company Strategy and Development Direction - The company aims to treat four cancer indications by the end of 2026, focusing on profitability and disciplined investments to strengthen its product portfolio [5][14] - Upcoming launches include pancreatic cancer and brain metastases, leveraging existing infrastructures from the GBM and lung cancer initiatives [19][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in the NSCLC launch, emphasizing the need for education and evidence generation to drive adoption [10][86] - The company remains committed to achieving profitability by 2027, with expected revenues from new indications contributing to this goal [33][77] Other Important Information - The company has a cash and investment balance of $1.034 billion, with plans to retire $561 million in convertible notes [34] - The PANOVA-3 trial results were positively received, and the company anticipates FDA approval for pancreatic cancer treatment by mid-next year [16][19] Q&A Session Summary Question: Can you provide insights on the lung cancer launch in Germany and Japan? - Management indicated that it is still early in the launch phase in Germany, while Japan presents a different market dynamic with a higher prevalence of lung cancer and a more favorable physician attitude towards device-based therapies [41][42] Question: What are the expectations for commercial reimbursement and NCCN guidelines? - Management reported that commercial reimbursement is progressing well, with expectations for Medicare reimbursement to follow, which is crucial for broader adoption [49][50] Question: What were the initial expectations for the lung cancer launch? - Management refrained from disclosing specific internal expectations but acknowledged that the ramp-up is slower than anticipated [54] Question: Can you clarify the gross margin trajectory? - Management expects gross margins to recover to the mid-70% range post-launch, with fluctuations during the transition period as new indications are introduced [70][71]